Dasatinib combined with multi-agent chemotherapy regimen in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia a prospective study from a single center  

作　　者：ZHANG Guangji 张广吉(State Experiment Hematol Key Lab,Natl Clin Blood Dis Res Center,Instit Hematol&Blood Dis Hosp,CAMS&PUMC,Tianjin 300020)

机构地区：[1]State Experiment Hematol Key Lab,Natl Clin Blood Dis Res Center,Instit Hematol&Blood Dis Hosp,CAMS&PUMC,Tianjin 300020

出　　处：《China Medical Abstracts(Internal Medicine)》2021年第2期119-120,共2页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To evaluate the efficacy and safety of dasatinib combined with a multi-agent chemotherapy regimen of Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph^(+)ALL)patients.Methods This prospective,single-arm,and open clinical study enrolled 30 adult Ph^(+)ALL patients who were newly diagnosed and treated from January 2016 to April 2018 in the center of this study.

关 键 词：REGIMEN PROSPECTIVE LYMPHOBLASTIC 

分 类 号：R733.71[医药卫生—肿瘤]